focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (4.545%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 22.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further information re Director's share transfer

12 Nov 2014 07:00

RNS Number : 7990W
Angle PLC
12 November 2014
 



For immediate release

12 November 2014

 

ANGLE plc

("ANGLE" or the "Company")

 

Further information re Director's share transfer

 

On 21 October 2014, the Company announced that Andrew Newland, Chief Executive of ANGLE, had agreed to transfer up to 3,500,000 ordinary shares of 10p each in the Company ("Ordinary Shares") as security for a loan facility in connection with his moving house (the "Announcement").

 

Following recent comments in the media relating to the Announcement, the Company wishes to provide the following information.

 

The agreement was entered into with Equity First Holdings LLC ("EFH") (the "Agreement") and, under the Agreement, which is a sale and repurchase agreement intended to provide financing to Andrew Newland, he transferred the legal and beneficial interest in 1,350,000 Ordinary Shares to EFH (the "transferred shares") in return for him receiving a payment from EFH of a sum equal to 62 per cent. of the three-day average mid-price per share (the "Starting Market Price") less a financing arrangement fee of 2 per cent.. Further details of the transfer made are set out below. As the legal and beneficial holder of the transferred shares, EFH may take any action it deems appropriate in relation to the transferred shares and is under no obligation to hold or retain the transferred shares.

 

On the maturity date of the Agreement (27 October 2016), Andrew Newland is contractually obliged to purchase the transferred shares or equivalent Ordinary Shares from EFH at a price equal to 67 per cent. of the Starting Market Price and EFH is contractually obliged to deliver the transferred shares or equivalent Ordinary Shares to Andrew Newland on payment.

 

If, prior to the maturity date, the value of the transferred shares falls to 49.6 per cent. or less of the Starting Market Price, Andrew Newland will be required to transfer further Ordinary Shares or provide cash to cover any difference.

 

The summary below is a clarification and correction of certain information contained in the Announcement. Andrew Newland remains interested in the transferred shares by reason of the repurchase obligation contained in the Agreement. Further announcements will be made if any further Ordinary Shares are transferred pursuant to the Agreement.

 

· Number of Ordinary Shares prior to transfer of shares under facility 7,054,686

· Number of Ordinary Shares transferred to EFH pursuant to the facility (and to be repurchased) to date 1,350,000

· Starting Market Price £0.851

· Number of Ordinary Shares with voting rights held after transactions and as a % of the Company 5,704,686 (12.61%)

· Total interest in Ordinary Shares and as a % of the Company(1) 7,054,686 (15.59%)

 

(1) As stated above, under the Agreement, Andrew Newland has agreed to repurchase the transferred shares or equivalent Ordinary Shares at the end of the two year period at a price calculated by reference to the Starting Market Price. For this reason he continues to have an interest in these Ordinary Shares and they are therefore included in his total interest in Ordinary Shares.

 

 

Garth Selvey, Chairman of ANGLE, commented: "Andrew has entered into this finance arrangement to bridge the purchase and renovation of a new house. Andrew believes strongly in the future value of ANGLE and does not want to sell his shares into the market. This facility enables him to return to his original position once the facility is repaid."

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Dr Christopher Golden (Nominated adviser)

Andy Roberts, Christian Hobart (Sales)

 

020 7397 8900

Buchanan

Mark Court, Sophie Cowles

020 7466 5000

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMMMMVZRGDZG
Date   Source Headline
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.